Oncology

Phase 1 data may support continued research of amphiphile lymph node–targeted immunotherapy in solid tumors.

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tu...

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.

Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.

Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.

Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.

Results from a retrospective study showed that chemoimmunotherapy did not prolong survival vs chemotherapy in a younger ES-SCLC population.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.

Panelists discuss how their key takeaways emphasize the importance of communication and collaboration between academic centers and community practices...

Panelists discuss how to implement hepatotoxicity monitoring protocols, counsel patients about avoiding hepatotoxic substances, and manage the infrequ...